Adaptive Biotechnologies/ADPT

$2.33

-4.3%
-
1D1W1MYTD1YMAX

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Ticker

ADPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Chad Robins

Employees

709

Headquarters

Seattle, United States

ADPT Metrics

BasicAdvanced
$354.03M
Market cap
-
P/E ratio
-$1.56
EPS
1.29
Beta
-
Dividend rate
$354.03M
1.28876
$9.08
$2.43
1.61M
4.66
4.496
-29.69%
-58.31%
-34.13%
2.079
1.148
1.921
-8.11%
-10.98%
20.06%

What the Analysts think about ADPT

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 5 analysts.
174.68% upside
High $10.00
Low $5.00
$2.33
Current price
$6.40
Average price target

ADPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-151.85% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$45.7M
20.58%
Net income
$-69.4M
37.97%
Profit margin
-151.85%
14.42%

ADPT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 44.91%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.40
-$0.33
-$0.35
-$0.48
-
Expected
-$0.38
-$0.35
-$0.34
-$0.33
-$0.34
Surprise
6.16%
-4.79%
3.28%
44.91%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Adaptive Biotechnologies stock?

Adaptive Biotechnologies (ADPT) has a market cap of $354.03M as of April 19, 2024.

What is the P/E ratio for Adaptive Biotechnologies stock?

The price to earnings (P/E) ratio for Adaptive Biotechnologies (ADPT) stock is 0 as of April 19, 2024.

Does Adaptive Biotechnologies stock pay dividends?

No, Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Adaptive Biotechnologies dividend payment date?

Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders.

What is the beta indicator for Adaptive Biotechnologies?

Adaptive Biotechnologies (ADPT) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Adaptive Biotechnologies stock price target?

The target price for Adaptive Biotechnologies (ADPT) stock is $6.4, which is 174.68% above the current price of $2.33. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Adaptive Biotechnologies stock

Buy or sell Adaptive Biotechnologies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing